Incyte Corporation (Nasdaq:INCY) today announced 2005 financial results and 2006 financial guidance, and reported on the company’s most advanced drug discovery and development programs including dexelvucitabine, or DFC, our Phase II compound for human immune deficiency virus (HIV).
